Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis
- 1 February 2016
- journal article
- Published by Elsevier BV in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1862 (2), 166-173
- https://doi.org/10.1016/j.bbadis.2015.11.001
Abstract
No abstract availableFunding Information
- Netherlands Organization for Scientific Research (NWO) (917.11.365)
- FP7 Marie Curie Actions IAPP (611979)
This publication has 33 references indexed in Scilit:
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathologyJournal of Allergy and Clinical Immunology, 2013
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel diseaseGut, 2011
- The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate ImmunityThe Journal of Immunology, 2009
- The Role of Dendritic Cells in the Development of Acute Dextran Sulfate Sodium ColitisThe Journal of Immunology, 2007
- Toll-Like Receptor 2 Controls Mucosal Inflammation by Regulating Epithelial Barrier FunctionGastroenterology, 2007
- Selective Adhesion-Molecule Therapy and Inflammatory Bowel Disease — A Tale of Janus?The New England Journal of Medicine, 2005
- Glucocorticoid resistance in inflammatory bowel diseaseJournal of Endocrinology, 2003
- Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cellsInternational Immunology, 2003
- Inflammatory Bowel DiseaseThe New England Journal of Medicine, 2002